Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paul Smock"'
Autor:
Robert W. Cross, Ira M. Longini, Stephan Becker, Karin Bok, David Boucher, Miles W. Carroll, Janet V. Díaz, William E. Dowling, Ruxandra Draghia-Akli, James T. Duworko, John M. Dye, Michael A. Egan, Patricia Fast, Amy Finan, Courtney Finch, Thomas R. Fleming, Joan Fusco, Thomas W. Geisbert, Anthony Griffiths, Stephan Günther, Lisa E. Hensley, Anna Honko, Ruth Hunegnaw, Jocelyn Jakubik, Julie Ledgerwood, Kerstin Luhn, Demetrius Matassov, Jeffrey Meshulam, Emily V. Nelson, Christopher L. Parks, Roxana Rustomjee, David Safronetz, Lauren M. Schwartz, Dean Smith, Paul Smock, Ydrissa Sow, Christina F. Spiropoulou, Nancy J. Sullivan, Kelly L. Warfield, Daniel Wolfe, Courtney Woolsey, Roland Zahn, Ana María Henao-Restrepo, César Muñoz-Fontela, Andrea Marzi
Publikováno v:
PLoS Pathogens, Vol 18, Iss 10 (2022)
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine “MARVAC” consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectiou
Externí odkaz:
https://doaj.org/article/eb16d630ec60444cb74dc537f414a98d
Autor:
Courtney L. Finch, Thomas H. King, Kendra J. Alfson, Katie A. Albanese, Julianne N. P. Smith, Paul Smock, Jocelyn Jakubik, Yenny Goez-Gazi, Michal Gazi, John W. Dutton, Elizabeth A. Clemmons, Marc E. Mattix, Ricardo Carrion, Thomas Rudge, Alex Ridenour, Sovann F. Woodin, Ruth Hunegnaw, Nancy J. Sullivan, Rong Xu
Publikováno v:
Vaccines, Vol 10, Iss 11, p 1935 (2022)
Marburg virus (MARV) is a virus of high human consequence with a case fatality rate of 24–88%. The global health and national security risks posed by Marburg virus disease (MVD) underscore the compelling need for a prophylactic vaccine, but no cand
Externí odkaz:
https://doaj.org/article/e79916c895fc4bc1a38bf77fcd628996
Autor:
Kavita Ramalingam Iyer, Alan Powell, Tim Corbidge, Robin Payne, David Estape, Ken Green, Phil Mcduff, Paul Smock, Jeff Blake, Johnson Jeffrey Charles, Scott Probst, Marc Pelletier
Publikováno v:
PDA journal of pharmaceutical science and technology. 70(3)
This paper is an interpretive response to Annex 2 of Eudralex—Volume 4; the European Union (EU) guidelines for good manufacturing practice (GMP) of medicinal products for human and veterinary use ([1][1]). It was written collaboratively, by a team